- Conditions
- Hemophilia A With Inhibitor
- Interventions
- efanesoctacog alpha, Emicizumab
- Drug
- Lead sponsor
- Versiti Blood Health
- Other
- Eligibility
- 0 Years to 17 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–37
of 13
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hemophilia A With Inhibitor
- Interventions
- Feiba
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hemophilia A
- Interventions
- HEMLIBRA
- Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- Up to 36 Months
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 10
- States / cities
- Hartford, Connecticut • New Haven, Connecticut • Lebanon, New Hampshire + 7 more
- Conditions
- Severe Hemophilia A, Moderate Hemophilia A
- Interventions
- Emicizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 13 Years to 69 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Miami, Florida • Oklahoma City, Oklahoma
- Conditions
- Hemophilia A, Factor VIII (FVIII)
- Interventions
- Half-life factor VIII based replacement therapy, Non-FVIII based replacement therapy
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 6 Months and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Haemophilic Pseudotumour
- Interventions
- Emicizumab
- Drug
- Lead sponsor
- Indiana Hemophilia &Thrombosis Center, Inc.
- Other
- Eligibility
- Not listed
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Hemophilia A, Factor VIII
- Interventions
- Eloctate, Adynovate, Emicizumab
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- Up to 17 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Hemophilia A
- Interventions
- Emicizumab, FVIII
- Drug
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 6 Years to 19 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Palo Alto, California • San Diego, California + 7 more
- Conditions
- Hemophilia A
- Interventions
- Nuwiq (low dose protocol), HEMLIBRA, Nuwiq (Atlanta protocol)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- Up to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 5 more
- Conditions
- Hemophilia A, Immune Tolerance
- Interventions
- FVIII, Emicizumab
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 0 Years to 12 Years · Male only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Von Willebrand Disease, Type 3
- Interventions
- Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates, von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates, Bypassing Agents
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 1 Month and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 6
- States / cities
- Sacramento, California • Gainesville, Florida • Lexington, Kentucky + 3 more
- Conditions
- Hemophilia A
- Interventions
- Emicizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 4
- States / cities
- Sacramento, California • Indianapolis, Indiana • Ann Arbor, Michigan + 1 more
- Conditions
- Hemophilia A
- Interventions
- Nuwiq, Octanate, Wilate, Emicizumab, Recombinant factor VIIa (rFVIIa), Activated prothrombin complex concentrate (aPCC)
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- Male only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia